Petrelintide is investigational long-acting human amylin analog (Zealand Pharma / Roche). Petrelintide is an experimental once-weekly injection that mimics amylin, a natural fullness hormone. It was developed by Zealand Pharma and is now co-developed with Roche for weight management.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Investigational: Phase 3 (ZUPREME program, started Sep 2026); not approved. Source: Roche starts three Phase 3 trials
Evidence tier: Phase 2 completed; Phase 3 ongoing
Get alerts on legal status changes ->
What it is
Petrelintide is an experimental once-weekly injection that mimics amylin, a natural fullness hormone. It was developed by Zealand Pharma and is now co-developed with Roche for weight management.
How it works
It activates amylin (and calcitonin) receptors to increase fullness and slow stomach emptying. It was engineered to stay stable in solution and last a week.
What it's researched for
Obesity and overweight, including people with type 2 diabetes and people with cardiovascular disease.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2024-12: ZUPREME-1 Phase 2 starts (source)
- 2025-11: Drug design paper published (J Med Chem) (source)
- 2026-09: Roche starts three Phase 3 trials (source)
Key trials and studies
- Phase 2, obesity (NCT06662539)
- Phase 2, with type 2 diabetes (NCT06926842)
- ZUPREME-5, Phase 3 with cardiovascular disease (NCT07843472)
- Phase 3 (NCT07843485)
- Phase 3 (NCT07843498)
FAQ
Is petrelintide FDA approved?
No. It entered Phase 3 trials in September 2026 and is not approved.
Who makes petrelintide?
It was discovered by Zealand Pharma and is co-developed with Roche.
Is petrelintide a GLP-1?
No. It is an amylin analog; Roche is also testing it together with a GLP-1/GIP drug.
Related peptides
- eloralintide FDA status and research
- cagrilintide FDA status and research
- amycretin FDA status and research
- pramlintide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Petrelintide or other peptides. Get alerts ->
Sources
- https://clinicaltrials.gov/study/NCT06662539
- https://clinicaltrials.gov/study/NCT06926842
- https://clinicaltrials.gov/study/NCT07843472
- https://clinicaltrials.gov/study/NCT07843485
- https://clinicaltrials.gov/study/NCT07843498
Editorial review - Last reviewed Oct 29, 2026